Blue Trust Inc. Increases Holdings in Amedisys, Inc. (NASDAQ:AMED)

Blue Trust Inc. grew its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 55.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 349 shares of the health services provider’s stock after buying an additional 124 shares during the quarter. Blue Trust Inc.’s holdings in Amedisys were worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. HBW Advisory Services LLC bought a new stake in Amedisys during the fourth quarter valued at approximately $38,000. Versant Capital Management Inc boosted its stake in shares of Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after acquiring an additional 183 shares during the last quarter. KBC Group NV purchased a new position in shares of Amedisys during the 3rd quarter worth $63,000. R Squared Ltd bought a new stake in shares of Amedisys during the 4th quarter valued at $203,000. Finally, Impact Partnership Wealth LLC purchased a new stake in shares of Amedisys in the 4th quarter worth $226,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Wednesday, February 12th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Performance

AMED opened at $91.57 on Friday. The company has a 50 day simple moving average of $91.26 and a two-hundred day simple moving average of $93.25. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a market cap of $3.00 billion, a P/E ratio of 36.34, a PEG ratio of 1.78 and a beta of 0.73. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Equities analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.